Amylyx Pharmaceuticals, Inc. (AMLX)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXHealthcare · Biotechnology
PrePre-market+1.05%$29.81
Close$29.50+2.24%AH$30.16-1.17%Now$29.81
Close$29.50+6.81%AH$30.16-1.17%since
Mkt Cap$3.79B
Float96.37M
O/S128.56M
PM VOL4K sh
$ Vol≈$110K
RVOL10.70×
Inst Own89.2%
SI13.8%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 27.73 | 29.58 | 27.50 | 29.50 | 1,860,722 |
| Nov 5, 2026 | 30.23 | 30.23 | 27.48 | 27.62 | 2,210,150 |
| Nov 4, 2026 | 30.65 | 30.68 | 27.90 | 29.40 | 1,586,283 |
| Nov 3, 2026 | 28.52 | 29.46 | 28.21 | 29.20 | 1,202,707 |
| Nov 2, 2026 | 28.84 | 29.50 | 27.61 | 28.04 | 1,161,835 |
| Oct 30, 2026 | 28.41 | 29.09 | 28.00 | 28.86 | 989,520 |
| Oct 29, 2026 | 28.13 | 29.13 | 28.09 | 28.68 | 905,466 |
| Oct 28, 2026 | 28.11 | 28.48 | 27.58 | 28.07 | 1,065,523 |
| Oct 27, 2026 | 27.28 | 28.32 | 26.86 | 28.30 | 1,122,472 |
| Oct 26, 2026 | 27.25 | 27.98 | 26.23 | 27.09 | 1,371,106 |
| Oct 23, 2026 | 28.46 | 28.46 | 27.06 | 27.20 | 1,158,895 |
| Oct 22, 2026 | 28.84 | 30.00 | 28.51 | 28.57 | 1,307,962 |
| Oct 21, 2026 | 28.96 | 29.77 | 28.81 | 29.03 | 1,626,563 |
| Oct 20, 2026 | 27.54 | 29.23 | 27.15 | 28.77 | 1,613,187 |
| Oct 19, 2026 | 26.48 | 27.35 | 26.27 | 27.33 | 1,380,993 |
| Oct 16, 2026 | 27.65 | 27.65 | 26.20 | 26.34 | 1,150,596 |
| Oct 15, 2026 | 27.68 | 28.34 | 27.45 | 27.65 | 882,656 |
| Oct 14, 2026 | 26.80 | 27.77 | 26.46 | 27.03 | 1,166,179 |
| Oct 13, 2026 | 27.49 | 27.69 | 26.80 | 26.85 | 1,059,785 |
| Oct 12, 2026 | 28.04 | 28.49 | 27.40 | 27.48 | 1,106,109 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not availableRatings Distribution
BUY10
HOLD1
SELL0
TOTAL11
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 MILNE GEORGE M JR | Director | Sale | 30.0K | $830.9K | Oct 5, 2026 |
 Cohen Joshua B | Co-Chief Executive Officer | Sale | 29.5K | $950.0K | Sep 10, 2026 |
 Mazzariello Gina | Chief Legal Officer | Sale | 9.5K | $309.1K | Sep 10, 2026 |
| Mazzariello Gina | Chief Legal Officer | Sale | 11 | $366.74 | Sep 10, 2026 |
 Bedrosian Camille L | Chief Medical Officer | Sale | 7.9K | $256.0K | Sep 10, 2026 |
| Bedrosian Camille L | Chief Medical Officer | Sale | 2.1K | $68.9K | Sep 10, 2026 |
Shareholders
89.2%
Institutional
(219)
6.9%
Insiderⓘ
(8)
0.0%
5%+ Owners
(0)
3.9%
Unattributed (incl. retail)ⓘ
Institutional89.2%
Insider6.9%
Unattributed (incl. retail)3.9%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
FMR LLC | 16.7M | 13.0% | 13F |
BlackRock, Inc. | 8.8M | 6.9% | 13F |
PERCEPTIVE ADVISORS LLC | 8.3M | 6.5% | 13F |
Perceptive Advisors LLC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 8.3M | 6.4% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2026 | 7.8M | 6.1% | 13G |
TCG Crossover Management, LLC | 6.2M | 4.9% | 13F |
Commodore Capital LP | 5.7M | 4.4% | 13F |
Jupiter Topco LLC | 5.2M | 4.1% | 13F |
Saturn V Capital Management LP | 4.6M | 3.6% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | 3.3% | 13F |
Sources: 13F, Form 4, 13D/13GO/S: 128.6M · as of 26 Oct 2026 · SEC cover page
Insiders & Institutional Holders
Insiders
- MILNE GEORGE M JRDirector
- Cohen Joshua BCo-Chief Executive Officer
- Mazzariello GinaChief Legal Officer
- Bedrosian Camille LChief Medical Officer
- FRATES JAMES MChief Financial Officer
- Klee Justin B.Co-Chief Executive Officer
- Firestone KarenDirector
- FONTEYNE PAUL R.Director
- Quimi DaphneDirector
- Zeiher Bernhardt GDirector
About
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases.
The company was established in 2013 and is based in Cambridge, Massachusetts.
Key Metrics
Market Cap$3.79B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership89.23%
based on 128.56M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
US
USIPO DateJan 7, 2022
Shares Outstanding128.56M
Authorized Shares
Float96.37M
52-Week Range
$10.83$41.14
$29.50(62nd percentile)
Volume
Average Daily Volume1.30M
1.86M today vs 1.30M avg(+44%)
30d Avg
1.30M
60d Avg
1.40M
90d Avg
2.15M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...